Cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival. Researchers report this at the ESMO 2014 Congress in Madrid. In Europe, about 70% of patients with cervical cancer are cured by either surgery or chemo-radiotherapy. Those patients with recurrent or secondary cancer have a very ...You have just read an article categorized health
titled Adding Cediranib to Chemo Improves Progression-Free Survival of Recurrent Cervical Cancer.
Written by:
editor - Monday, September 29, 2014
There are currently no comments for "Adding Cediranib to Chemo Improves Progression-Free Survival of Recurrent Cervical Cancer"
Post a Comment